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Abstract 
Background: A targeted drug nanoparticle (NP) delivery system has shown potential as a possible cancer treatment. 
Given its merits, such as its selective distribution at tumor sites and its controllable drug release, drug-loaded NPs can 
be effectively delivered to selected organs and targeted cells, thus enhancing its antitumor efficiency and reducing its 
toxicity.
Methods: We reported that hyaluronic acid (HA)-coated chitosan NPs promoted the drug delivery of 5-fluorouracil 
(5-Fu) into tumor cells that highly expressed CD44.
Results: Our new findings suggested that HA-coated chitosan NPs enhanced drug accumulation by effectively 
transporting NPs into CD44-overexpressed tumor cells, and they also resulted in mitochondrial damage induced by 
the production of reactive oxygen species (ROS). Compared to free drug and uncoated NPs, HA-coated chitosan NPs 
exhibited stronger inhibition rates and induced obvious apoptosis in CD44-overexpressed A549 cells.
Conclusions: Biocompatible and biodegradable HA-coated chitosan NPs were developed to encapsulate a chemo-
therapeutic drug (5-Fu) to enhance drug accumulation in tumor cells and to improve the agent’s antitumor efficiency 
by offering targeted drug delivery via CD44.
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Background
Current cancer treatment primarily depends on surgi-
cal operations and chemotherapy to fight against cancer. 
Although chemotherapeutic drugs are effective at killing 
tumor cells, some have several drawbacks, including their 
nonselective distribution, drug toxicity, and unexpected 
side effects to normal tissues, which have limited these 
agents’ clinical use [1–3]. There were few effective anti-
cancer drugs available that would specifically kill cancer 
cells and not damage normal cells. Therefore, the onset of 
side effects and toxicity induced by the anti-tumor drugs 
was probably inevitable and resulted in the failure of 
chemotherapy. CD44 is a multistructural and multifunc-
tional cell-surface molecule involved in cell proliferation, 
cell differentiation, cell migration, and angiogenesis, and 
it is also implicated in cell signaling for survival [4–7]. 
Compared with normal cells, CD44 showed a higher 
expression level in many cancer cells and was recognized 
as a potential therapeutic target in cancer therapy [8, 9]. 
Hyaluronic acid (HA) is a type of linear mucopolysaccha-
ride composed of alternately repeated N-acetylglucosa-
mine and glucuronic di-saccharide, and it constitutes the 
main component of the extracellular matrix. Owing to its 
ability to specifically target CD44 receptors, HA has been 
frequently modified with a drug carrier to enhance drug 
delivery in CD44-overexpressed tumor cells to effectively 
inhibit tumor growth [10–15].
Open Access
Journal of Nanobiotechnology
*Correspondence:  liangzhao79@163.com; shiyijie119@163.com 
1 School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, 
People’s Republic of China
Full list of author information is available at the end of the article
Page 2 of 12Wang et al. J Nanobiotechnol  (2017) 15:7 
Nanoparticles (NPs), an effective drug delivery system, 
have shown potential clinical application in the treat-
ment of cancer. In recent years, numerous studies con-
firmed the role of NPs in enhancing the accumulation of 
drugs at the tumor site and controlling the drug release 
rate to prolong curing times [16–18]. Furthermore, 
related studies showed how the internalization of some 
NPs increased the generation of reactive oxygen species 
(ROS) and enhanced synergistic antitumor efficacy by 
activating mitochondria-meditated apoptosis [19–22]. 
To investigate whether drug-loaded NPs could induce 
more cell apoptosis, and to further determine whether 
NPs activated the ROS-mediated mitochondrial apopto-
sis pathway, we designed HA-coated chitosan (CS) NPs 
to enhance antitumor efficiency via targeted drug deliv-
ery by way of the interactions between HA and CD44. 
Then, 5-fluorouracil (5-Fu), as a model anticancer drug, 
was used to prepare 5-Fu-loaded HA-coated CS NPs by 
the ion gelation method, and the loading efficiency (LE), 
encapsulation efficiency (EE), and drug release process 
were also explored in vitro. The cellular uptake and dis-
tribution of HA-coated NPs were investigated in A549 
cells (which overexpress CD44 receptors) and HepG2 
cells (those that feature low-expressing CD44 receptors) 
to evaluate NPs’ ability to specifically target the CD44 
receptors. Cell cytotoxicity and cellular apoptosis were 
assessed to confirm ROS-mediated mitochondrial apop-




CS, with a degree of deacetylation of 80% and a molecu-
lar weight of approximately 400 kDa, was purchased from 
Haixin Biological Product Co., Ltd. (Ningbo, People’s 
Republic of China); 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) and rhodamine B 
(RhB) were purchased from Sigma-Aldrich Co. (St Louis, 
MO, USA); sodium hyaluronate (molecular weight: 
125  kDa) was obtained from Shandong Freda Biochem 
Co, Ltd (Shandong, People’s Republic of China); and 5-Fu 
was purchased from Nantong Jinghua Pharmaceutical 
Co, Ltd. (Nantong, People’s Republic of China). The other 
chemicals that were purchased were of analytical grade 
and were obtained from Sigma-Aldrich Co. A549 cells 
and HepG2 cells were obtained from Jinzhou Medical 
University (Jinzhou, People’s Republic of China).
Preparation of 5‑Fu‑loaded HA‑coated CS NPs
According to a previous protocol [23, 24], we first 
prepared 5-Fu-loaded CS NPs using the ion gelation 
method. To prepare 5-Fu-loaded NPs, 1 mg of 5-Fu was 
added into a solution containing 500  mL of acetic acid 
(2%, v/v) and 20 mg of CS, and the obtained sodium trip-
olyphosphate reserve liquid was added into the CS solu-
tion by slow dropping under magnetic stirring for 5 h at 
room temperature. Finally, 5-Fu-loaded CS NPs formed 
instantaneously and the NPs were precipitated and resus-
pended in distilled water, followed by the addition of HA 
sodium salt solution under oscillation for 30 min. Owing 
to the strong electrostatic interaction between the cati-
onic amino group of CS and the anionic carboxyl group 
of HA, HA was conjugated at the surface of the CS NPs 
by charge adsorption to obtain 5-Fu-loaded HA-coated 
CS NPs. The obtained 5-Fu loaded HA coated CS NPs 
were precipitated by centrifugation at 16,000  rpm for 
20  min, then the NPs were separated and washed with 
distilled water for three times to remove the free HA and 
chitosan. The structure of HA-coated CS NPs was inves-
tigated using IRAffinity-1 infrared (IR) spectroscopy, and 
the physical characteristics of NPs  including their mor-
phology, particle size, zeta potential, and polydispersity 
index  were determined by transmission electron micro-
scope (TEM) (JEM-1200EX; JEOL, Tokyo, Japan) and 
Zetasizer (Nano ZS90; Malvern Instruments, Malvern, 
UK). The LE, EE, and the in  vitro drug-release process 
were also explored [25].
MTT
The cytotoxicity of free 5-Fu and 5-Fu-loaded NPs of dif-
ferent concentrations were evaluated by MTT assay. Cells 
(80 μL per well, about 1 × 104 cells/well) were cultured 
in clear-bottom 96-well tissue culture plates. Test groups 
including free 5-Fu, 5-Fu-loaded HA-coated CS NPs, and 
a combination of free HA and 5-Fu-loaded HA-coated 
CS NPs were added and the cells were incubated for 48 h. 
The culture medium was removed and 100 μL of Dulbec-
co’s Modified Eagle’s Medium (DMEM) was added. Then, 
15 μL of MTT with a concentration of 5  mg/mL was 
added into the wells and incubated with the cells for 4 h 
at 37  °C. Finally, 150 μL of dimethyl sulfoxide (DMSO) 
was added into each well followed by the gentle mixing 
on an orbital shaker for 1  h at room temperature. The 
absorbance was measured at 570 nm for each well by an 
absorbance microplate reader (Synery-2; BioTek Instru-
ments, Winooski, VT, USA). All experiments were per-
formed in triplicate.
In vitro cellular uptake
In order to observe the intracellular distribution of NPs, 
RhB as a fluorescent marker was encapsulated in NPs 
to label their location within the cells. RhB-labeled HA-
coated CS NPs were incubated with cells in the medium 
containing free HA or no HA for a certain period of 
time. The nucleus was stained with Hoechst (blue) for 
15  min at 37  °C and the mitochondria were stained by 
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Mito tracker (green). Finally, the internalizing process of 
RhB-labeled NPs was observed by detecting the fluores-
cence of RhoB (Ex:572 nm, Em: 591 nm), hoechst33342 
(Ex:352 nm, Em: 455 nm) and Mito tracker (Ex:495 nm, 
Em: 519 nm) when culturing the cells on the built-in cul-
ture stage of confocal laser scanning microscopy (CLSM) 
(FluoView FV10i; Olympus Corporation, Tokyo, Japan) 
at 37  °C under 5% CO2 and humidity control, enabling 
long-term live cell imaging. For cell culture, a glass bot-
tom dish, 35  ×  10  mm, advanced TC (treated) was set 
on the stage incubator. On the detection side,the FV10i 
was fitted with a newly developed spectral system featur-
ing two fluorescence channels supplied by a novel grat-
ing, beam splitter and slit arrangement. In addition, each 
channel was fitted with a variable barrier filter which was 
set automatically to match the wavelength range for each 
fluorescence dye in use.
JC‑1 staining
The mitochondrial membrane potential change was 
measured using JC-1 (Beyotime Institute of Biotech-
nology, Haimen, People’s Republic of China) and it was 
observed under CLSM (FluoView FV10i; Olympus Cor-
poration). Briefly, A549 cells (1 × 105) were seeded in a 
glass-bottomed dish (NEST, φ15  mm; People’s Republic 
of China) and cultured for 24 h under 5% CO2 at 37 °C. 
After that, the cells were treated with fresh medium 
containing 5-Fu, 5-Fu-loaded HA-coated CS NPs, and a 
combination of free HA and 5-Fu-loaded HA-coated CS 
NPs, respectively, for another 24 h. After incubation, the 
medium was removed and the cells were washed twice 
with cold phosphate buffered saline (PBS); the cells were 
then stained with JC-1 (5 mg/mL) at 37 °C for 30 min in 
the dark. Stained cells were washed twice with cold PBS 
to remove free dye and they were observed by CLSM.
ROS determination and endoplasmic reticulum stress
To investigate the effects of NP exposure on the pro-
duction of ROS, as well as on the function of both 
endoplasmic reticulum (ER) stress and the mitochon-
dria, mitochondrial permeability was detected after NP 
exposure using the JC-1 staining method; the degree of 
ER stress was also evaluated by observing the morpho-
logical changes of the ER under CLSM. The intracellular 
DCF fluorescence intensity, which is excited at 485  nm 
and emitted at 530 nm, was detected using a microplate 
reader (Synery-2; BioTek Instruments) to investigate the 
extent of oxidative stress. To examine the role of NPs on 
ROS-induced mitochondrial disorders after NP expo-
sure, N-acetyl-l-cysteine (NAC), an ROS inhibitor, was 
induced to determine the vital effect of oxidative stress 
on mitochondrial morphology dysfunction induced by 
NP exposure.
Cell apoptosis study
The apoptotic effects of 5-Fu-loaded HA-coated CS NPs 
on CD44 overexpressed A549 cells were determined 
using the Annexin V-FITC Apoptosis Detection Kit 
(Abcam plc, Cambridge, UK). Tested cells were seeded in 
6-well plates (Corning, Inc., Corning, NY, USA) at a den-
sity of 1 × 105 cells/well in 1 mL of medium. After 24 h, 
the cells were treated, respectively, with fresh medium 
containing 5-Fu, 5-Fu-loaded HA-coated CS NPs, and the 
combination of free HA and 5-Fu-loaded HA-coated CS 
NPs. After 24 h of treatment at 37 °C with 5% CO2, cells 
were digested with 0.25% trypsin and washed twice with 
cold PBS. The collected cells were stained with Annexin 
V-FITC and propidium iodide (PI; provided in the kit) in 
the dark and analyzed by flow cytometry (BD, Franklin 
Lakes, NJ, USA).
Western blot assay
The related protein expressions in A549 cells treated with 
various formulations were detected by means of Western 
blot analysis. A549 cells were harvested and lysated in 
radioimmunoprecipitation assay (RIPA) buffer (150 mM 
of NaCl, 1% NP-40, 1% sodium dodecyl sulfate (SDS), 
1  mM Phenylmethanesulfonyl fluoride (PMSF), 10 ug/
mL of leupeptin, 1 mM of aprotinin, 50 mM of Tris–Cl, 
pH 7.4). The cells were incubated in ice for 30 min and 
lysates were centrifuged for 20  min at 13,000  rpm to 
acquire the supernatant. The protein concentration was 
determined by the BCA Protein Assay Kit (Beyotime 
Institute of Biotechnology). The protein lysates were 
separated by 12% SDS–polyacrylamide gel electropho-
resis (PAGE) and transferred to polyvinylidene fluoride 
(PVDF) membranes (BioTrace; Pall Corporation, New 
York, USA). After blocking with 1% bovine serum albu-
min (BSA) for 1 h at room temperature, membranes were 
incubated with 1:1000 diluted primary antibody over-
night at 4  °C. Then, the membranes were washed and 
incubated with 1:10,000 diluted secondary antibodies for 
1 h at room temperature. The membranes were washed 
again and stained with enhanced chemiluminescence 
(ECL). The protein bands were visualized by ECL detec-
tion reagents and captured by the Bio-RAD Gel Imaging 
System.
Results
The preparation and characteristics of various kinds of NPs
The construction of HA-coated CS NPs was investigated 
using IR spectroscopy, as shown in Fig. 1a. It was found 
that the characteristic absorption peaks of CS and HA 
were all visible along the spectrum of the HA-coated CS 
NPs. This suggests that CS and HA, as materials, were 
involved in NP formation. Compared with the spectra of 
CS and HA, there were no obvious new absorption peaks 
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that appeared along the spectrum of HA-coated CS NPs, 
thus indicating that no new bonds were formed dur-
ing the preparation of HA-coated CS NPs. HA absorbed 
the surface of the CS NPs via electrostatic interactions 
between CS and HA, rather than by chemical conjuga-
tion. The characteristics of various kinds of NPs were 
investigated to determine their particle size, zeta poten-
tial, and morphology. The results in Table  1 show that 
the size of 5-Fu-loaded HA-coated CS NPs was smaller 
and more homogeneously distributed; moreover, the 
morphology of the NPs was subspheroidal and its zeta 
potential was positive and valued at 15.6 ± 3.7 mV. The 
average EE of the CS NPs and HA-coated CS NPs was 
85.2  ±  5.44% and 86.7  ±  6.18%, respectively, indicat-
ing that no drugs were leaking from the CS NPs during 
the HA coating process. Compared with free drug and 
5-Fu-loaded CS NPs, 5-Fu-loaded HA-coated CS NPs 
showed a sustained and slower biphasic release pro-
file, and over 75% of the total 5-Fu was released at 48 h. 
This suggests that the coating of HA at the surface of CS 
NPs may have increased the particle size, and that the 
medium solution took longer to penetrate through the 
polymer matrix into the interior of the NPs, thus leading 
to sustained and smooth drug release. 
MTT analysis
The MTT results shown in Fig.  2 demonstrate that 
naked HA-coated CS NPs at a certain concentration 
(ranging from 0.1 to 1.0  mg/mL) did not inhibit the 
proliferation of A549 cells and HepG2 cells, and that 
the viability ratios were over 85%, indicating its good 
excellent biocompatibility and nontoxicity. Compared 
Fig. 1 Characterization of 5-Fu-loaded HA-coated CS NPs. a FTIR spectra of chitosan, HA and HA-coated CS NPs; b DLS analysis of 5-Fu-loaded 
HA-coated CS NPs; c accumulated release of drug-loaded NPs in the medium at pH 7.4; and TEM images of 5-Fu-loaded HA-coated CS NPs (d) and 
5-Fu-loaded CS NPs (e). The results are expressed as the mean ± SD (n = 3)
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with the free drug and 5-Fu-loaded uncoated CS NPs, 
5-Fu-loaded HA-coated CS NPs showed higher cyto-
toxicity in both cells. The 50% maximal inhibitory 
concentration (IC50) values in A549 cells and HepG2 
cells treated with 5-Fu-loaded HA-coated CS NPs were 
8.0 and 6.7  μg/mL at 48  h, respectively. Interestingly, 
with the pre-addition of free HA into both cells, cells 
treated with NPs showed different changing trends in 
their ability to inhibit the effects of treated cells. With 
the addition of HA into A549 cells (those overexpress-
ing CD44 receptors), the cytotoxic effects of CS NPs 
were significantly inhibited and the IC50 value in A549 
cells treated with 5-Fu-loaded HA-coated CS NPs was 
reduced to 13.1  μg/mL at 48  h. Conversely, the addi-
tion of free HA had no obvious effects on the HepG2 
cells’ (those with low-expressing CD44 receptors) cell 
proliferation, and the IC50 value in cells treated with 
5-Fu-loaded HA-coated CS NPs was 7.2 μg/mL at 48 h. 
This suggested that in A549 cells (those overexpressing 
CD44 receptors), HA as a targeting ligand improved the 
internalization of NPs in those cells that overexpressed 
the CD44 receptor, and 5-Fu-loaded HA-coated CS 
Table 1 Key parameters of 5-Fu loaded CS NPs and 5-Fu loaded HA coated CS NPs
Group Diameter (nm) Zeta potential (mV) Polydispersity Encapsulation efficiency %
5-Fu loaded CS NPs 98.5 ± 5.4 21.9 ± 2.6 0.31 ± 0.09 85.2 ± 5.44
5-Fu loaded HA coated CS NPs 118.9 ± 9.8 15.6 ± 3.7 0.19 ± 0.05 86.7 ± 6.18
Fig. 2 Viability of A549 cells and HepG2 cells. Viability of A549 cells (a) and HepG2 cells (b) after incubation with naked HA-coated CS NPs. Viability 
of A549 cells (c) and HepG2 cells (d) after incubation with free 5-Fu, 5-Fu-loaded CS NPs, 5-Fu-loaded HA-coated CS NPs and the combination of free 
HA and 5-Fu-loaded HA-coated CS NPs for 48 h. The results are expressed as the mean ± SD (n = 3)
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NPs showed the highest drug cytotoxicity, as compared 
with free drugs and drug-uncoated HA NPs. With the 
mediation of free HA, HA in the medium and 5-Fu-
loaded HA-coated CS NPs competed to bind with its 
CD44 receptor; the uptake of 5-Fu-loaded HA-coated 
CS NPs was reduced, thus decreasing the intracellu-
lar distribution and concentration of drugs, leading to 
the inhibition of cytotoxicity. This further proved that 
5-Fu-loaded HA-coated CS NPs may be internalized via 
HA-mediated uptake.
Uptake ability of different kinds of NPs in cells
When RhB-labeled HA-coated CS NPs were co-incu-
bated with cells for 6 h (Fig. 3), NPs were first adsorbed 
on the surface of the cell membrane and they were fur-
ther internalized into the cell’s interior, represented by 
the dispersion of intense red fluorescent dots in the 
cytoplasm. Compared with the weak fluorescent dots 
observed in HepG2 cells treated with HA-coated CS NPs, 
stronger and intense red fluorescence emitted by RhB-
labeled HA-coated CS NPs appeared in the cytoplasm 
of A549 cells that highly expressed CD44. This indicated 
that HA-coated CS NPs effectively promoted drug accu-
mulation in those cancer cells where CD44 was highly 
expressed on the cell surface; specific binding between 
HA and CD44 might facilitate the uptake of HA-coated 
CS NPs. To further clarify the internalization process of 
HA-coated CS NPs mediated by the interaction between 
HA and CD44, we used free HA as a competitive inhibi-
tor of CD44 receptors to pre-coincubate the cells to 
investigate the competitive cellular uptake mechanism of 
NPs. The results showed that after A549 cells were cul-
tured with HA-coated CS NPs, intense red fluorescence 
was observed inside the cells. However, following the 
addition of 2 mg/mL of free HA into the medium, intra-
cellular fluorescent intensity was significantly reduced 
and the NP uptake was significantly inhibited. This sug-
gested that HA-coated CS NPs selectively bound to CD44 
receptors and accelerated the internalization of NPs into 
cells. Free HA that existed in the medium had competed 
with HA-coated CS NPs to bind to CD44 receptors on 
the cell surface, thus resulting in receptor saturation 
and preventing the transportation of NPs into the cells. 
In contrast, the addition of HA had no obvious effects 
on the internalization of HA-coated CS NPs in HepG2 
cells with a low expression of CD44. Furthermore, the 
obvious co-location between NPs and mitochondria was 
observed, and it was demonstrated that HA-coated NPs 
were situated at the mitochondria, where they interfered 
with the integrity and function of the mitochondria. This 
indicated that mitochondrial-mediated apoptosis may 
have been triggered.
JC‑1 staining
In order to further investigate the effects of HA-coated 
NPs on the integrity and permeability of mitochon-
dria, JC-1 staining was performed to detect the poten-
tial change in the mitochondria by observing the color 
variations between green fluorescence (JC-1 mono-
mer) and red fluorescence (JC-1 aggregation). As illus-
trated in Fig.  4, the intensity of the green fluorescence 
in cells treated with HA-coated CS NPs was significantly 
enhanced, indicating that HA-coated NPs were located at 
the mitochondria; these NPs damaged the integrity of the 
mitochondria, thus causing a significant decrease in the 
mitochondrial membrane potential. With the increas-
ing addition of HA-coated NPs, the membrane potential 
continued to decline in a dose-dependent pattern, repre-
sented by a proportional decrease in the intensity of both 
red fluorescence and green fluorescence. Additionally, it 
was demonstrated that the addition of free HA reduced 
the accumulation of NPs in the mitochondria, ultimately 
maintaining the integrity and permeability of the mito-
chondria through binding competition.
The effect of NP exposure on ROS generation and ER stress
As shown in Fig. 5, we found that HA-coated NPs gener-
ated the production of ROS and damaged the integrity of 
the mitochondria by decreasing the mitochondrial mem-
brane potential. With increasing dosages of NPs, a strong 
green fluorescence was observed in cells, indicating that 
NPs accelerated the production of intracellular ROS, 
showing a dose-dependent relationship. In addition, the 
intensity of the green fluorescence from the JC-1 mono-
mer continued to increase, suggesting that the mitochon-
drial membrane potential exhibited a downward trend in 
a dose-dependent manner. Furthermore, the degree of 
ER stress was significantly enhanced by the induction of 
HA-coated NP exposure. However, when given antioxi-
dant NAC to inhibit ROS generation, the mitochondrial 
membrane potential increased. This finding indicated 
that HA-coated NPs induced the massive production of 
oxygen free radicals in cells and damaged the integrity of 
the mitochondrial membrane by reducing its membrane 
potential, thus resulting in the activation of the mito-
chondrial-mediated apoptosis pathway.
Cell apoptosis and necrosis
When A549 cells were incubated with free 5-Fu, 5-Fu-
loaded NPs, and 5-Fu-loaded HA-coated CS NPs, respec-
tively, the ratios of double (Annexin V/PI)-positive 
cells in A549 cells were analyzed by flow cytometry. As 
shown in Fig.  6, as compared with free 5-Fu and 5-Fu-
loaded uncoated NPs, 5-Fu-loaded HA-coated CS NPs 
induced the highest apoptosis effects, and the ratio of 
Page 7 of 12Wang et al. J Nanobiotechnol  (2017) 15:7 
double (Annexin V/PI)-positive cells in A549 cells was 
64.3%. This suggested that HA-coated CS NPs enhanced 
drug delivery and accumulation, as mediated by HA and 
CD44; further NP exposure activated the ROS-mediated 
mitochondrial apoptosis pathway. Therefore, the anti-
tumor efficacy of the drug had significantly improved. 
With the addition of free HA, the internalization of drug-
loaded NPs was limited due to the CD44-based binding 
competition between HA and HA-coated CS NPs; more-
over, the apoptosis effects were also decreased, and the 
ratio of double (Annexin V/PI)-positive cells in the A549 
cells was 27.1%. When cells were treated with NAC and 
5-Fu-loaded HA-coated CS NPs, the apoptosis effects 
significantly decreased and the ratio of double (Annexin 
V/PI)-positive cells in the A549 cells was 16.4%. This may 
indicate that the addition of NAC inhibited the ROS gen-
eration induced by the internalization of NPs, and it fur-
ther blocked the ROS-mediated mitochondrial apoptosis 
pathway, thus limiting the induction of apoptosis.
Western blot analysis
The effects of 5-Fu or 5-Fu-loaded NPs on the mito-
chondrial apoptosis pathway were investigated by con-
ducting Western blot to examine some mitochondrial 
Fig. 3 The in vitro cellular distribution of RhB-labeled HA-coated CS NPs following the incubation of A549 cells and HepG2 cells. The scale bar in all 
figure parts is 100 μm
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apoptosis-related factors such as cytochrome C, caspase 
precursor, and apoptosis-inducing factors. The results 
(Fig. 7) showed that compared with free 5-Fu and 5-Fu-
uncoated NPs, 5-Fu-loaded HA-coated CS NPs induced 
the highest apoptosis effects, represented by the highest 
expression of cytochrome C, caspase-9, and cleaved cas-
pase-3 in A549 cells; the expression level of Bcl-2 was the 
lowest. This finding highlighted that more 5-Fu-loaded 
HA-coated CS NPs had accumulated in the cells due to 
the interaction between HA and CD44, and this led to 
significant apoptosis. Furthermore, it was observed that 
cytochrome C in the cytoplasm treated with 5-Fu-loaded 
HA-coated CS NPs was expressed at the highest level, 
proving that HA-coated CS NPs damaged the integrity of 
the mitochondria and decreased its membrane potential, 
thus resulting in activation of the mitochondrial apop-
tosis pathway. Following NP exposure, the mitochon-
drial membrane potential was reduced and cytochrome 
C was released from the mitochondria to the cytoplasm; 
furthermore, an important anti-apoptotic protein (Bcl-
2) was inhibited and initiated the activation of apopto-
sis-related proteins such as caspase 9 and 3, eventually 
aiding in the significant apoptosis of tumor cells. When 
given the antioxidant NAC, the increased expressions of 
Fig. 4 Changes in the mitochondrial membrane potential after incubating HA-coated CS NPs with A549 cells. The scale bar in all figure parts is 
100 μm
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caspase 9 and cleaved caspase 3 were suppressed and the 
expression of cytochrome C in the cytoplasm was also 
reduced. This indicated that NAC decreased the produc-
tion of ROS generated by the exposure of HA-coated CS 
NPs and it maintained the integrity of the mitochondrial 
membrane potential. Therefore, the ability to transfer 
cytochrome C from the mitochondria to the cytoplasm 
was blocked and the ROS-mediated mitochondrial apop-
tosis pathway was further inhibited.
Discussion
The important physiological function of mitochondria 
is to produce adenosine triphosphate (ATP) by oxida-
tive phosphorylation; they are also involved in apoptosis 
and they regulate calcium levels in the cytoplasm and 
mitochondria [26, 27]. It was found that the occurrence 
and development of tumorigenesis were associated with 
disordered mitochondrial function. The integrity of the 
mitochondria was more susceptible to damage by the 
induction of ROS [28], thus leading to difficulties in tran-
scription and in the synthesis of related peptides, further 
triggering the mitochondrial-mediated apoptotic path-
way. Therefore, researchers managed to interfere with the 
integrity and function of the mitochondria to promote 
cell death. NPs, as a nanoscale carrier, showed excellent 
value and potential for improving drug delivery. As their 
particle sizes range from 10 to 500 nm, drug-loaded NPs 
can be selectively retained at the tumor site (known as 
the EPR effect), and they can conjugate specific targeting 
molecules at the NPs’ surface to achieve active targeted 
therapy by binding with specific cell-surface recep-
tors [29, 30]. In addition, the internalization of some 
NPs could specifically occur at the mitochondria, thus 
increasing ROS generation and enhancing synergistic 
antitumor efficacy by activating mitochondrial-meditated 
apoptosis [31, 32]. In our study, we also found that HA 
presented as an active targeting factor and was absorbed 
at the surface of the CS NPs; these NPs bound to specific 
Fig. 5 ROS generation in A549 cells treated with HA-coated NPs, ER staining with the ER Tracker blue–white DPX probe, and image changes of the 
mitochondrial membrane potential following treatment with HA-coated NPs. The scale bar in all figure parts is 100 μm
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CD44 receptors on the CD44-overexpressed tumor cell 
surface, thus improving the targeting efficiency of NPs 
and accelerating drug accumulation within the cells. 
Importantly, HA-coated CS NPs were distributed in the 
mitochondria and they generated the massive production 
of ROS and activated ROS-induced mitochondrial dis-
orders. This suggested that compared with free 5-Fu and 
5-Fu-loaded uncoated CS NPs, 5-Fu-loaded HA-coated 
CS NPs enhanced CD44 receptor-mediated endocyto-
sis and led to increased intracellular uptake of the drug. 
Furthermore, HA-coated CS NPs also generated the mas-
sive production of ROS and activated the mitochondrial 
apoptotic pathway, thus enhancing the drug’s synergistic 
antitumor effects.
Conclusions
Biocompatible and biodegradable HA-coated CS NPs 
were developed to encapsulate a chemotherapeutic drug 
(5-Fu) to enhance drug accumulation in tumor cells and 
to improve the drug’s antitumor efficiency by achiev-
ing targeted drug delivery via CD44. The results showed 
that the size of the 5-Fu-loaded HA-coated CS NPs was 
smaller and more homogenously distributed; moreo-
ver, the morphology of NPs was subspheroidal and their 
zeta potential was positive and valued at 15.6 ± 3.7 mV. 
It is important to note that 5-Fu loaded HA-coated CS 
NPs showed a sustained and biphasic release profile, as 
75% of the total 5-Fu was released in 48 h. We found that 
compared with free drugs and uncoated NPs, particularly 
Fig. 6 Cell apoptosis determined by Annexin V–fluorescein isothiocyanate/propidium iodide staining. The results were determined after incubation 
with free 5-Fu, 5-Fu-loaded CS NPs, 5-Fu-loaded HA-coated CS NPs, free HA and 5-Fu-loaded HA-coated CS NPs, and 5-Fu-loaded HA-coated CS NPs 
combined with NAC for 24 h (n = 3)
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given the interaction between HA and CD44, HA-coated 
NPs enhanced drug accumulation by effectively trans-
porting NPs into CD44-overexpressed tumor cells and 
inducing cell apoptosis. Exposure of 5-Fu-loaded HA-
coated NPs enhanced the generation of ROS and resulted 
in ROS-induced disorders in mitochondrial function, 
further activating the mitochondrial-mediated apoptosis 
pathway.
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